Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A placebo-controlled clinical study of AXO-AAV-OPMD for oculopharyngeal muscular dystrophy (OPMD)

Trial Profile

A placebo-controlled clinical study of AXO-AAV-OPMD for oculopharyngeal muscular dystrophy (OPMD)

Planning
Phase of Trial: Phase I

Latest Information Update: 03 Jan 2019

At a glance

  • Drugs AXO-AAV-OPMD (Primary)
  • Indications Oculopharyngeal muscular dystrophy
  • Focus Adverse reactions
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 03 Jan 2019 According to an Axovant Sciences media release, initiation of clinical program is expected in the second half of 2019.
    • 11 Jul 2018 New trial record
    • 08 Jul 2018 According to an Axovant Sciences media release, the company expects to start this trial in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top